Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat.
Fenspiride, an antiinflammatory drug with low anti-cyclooxygenase activity, administered orally at 60-200 mg/kg inhibited neutrophil migration into peritoneal and air pouches cavities as well as exudation into peritoneal cavities induced by endotoxin but not induced by carrageenin. Up to 100 microM, fenspiride failed to inhibit the in vitro release of a neutrophil chemotactic activity by endotoxin-stimulated macrophages and the in vivo migration into the peritoneal cavities induced by the supernatant of those macrophages. The release of tumour necrosis factor by stimulated macrophages was inhibited by fenspiride in a dose-dependent manner. These results suggest that the antiinflammatory effects of fenspiride are associated with the inhibition of the tumour necrosis factor release by resident macrophages.
Cunha
F Q
FQ
Departmento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Brazil.
Boukili
M A
MA
da Motta
J I
JI
Vargaftig
B B
BB
Ferreira
S H
SH
D000284:Administration, Oral; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D002351:Carrageenan / Q000633:toxicity; D002465:Cell Movement / Q000187:drug effects; D004731:Endotoxins / Q000633:toxicity*; D016209:Interleukin-8 / Q000378:metabolism / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D010529:Peritoneal Cavity / Q000166:cytology; D051381:Rats; D017208:Rats, Wistar; D013141:Spiro Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D004731:Endotoxins; D016209:Interleukin-8; D013141:Spiro Compounds; D014409:Tumor Necrosis Factor-alpha; D002351:Carrageenan